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Abbreviation Full Name 
TLC Thin Layer Chromatography 
HPLC High Performance Liquid Chromatography  
CC Column Chromatography  
IR Infra-Red  
[α] Optical rotation 
UV Ultravolet 
MS Mass Spectrometry  
ESI-MS Electrospray Ionization Mass Spectrometry  
FT-MS Fourier Transform Mass Spectroscopy 
TOF-MS Time of Llight Mass Spectrometry 
TMS Trimethylsiyl 
NMR Nuclear Magnetic Resonance   
1H-NMR 1H nuclear magnetic resonance   
13C-NMR 13C nuclear magnetic resonance 
DEPT Distortionless Enhancement by Polarlization Transfer  
HSQC 1H -detected heteronuclear sigle quantum correlation  
HMBC 1H -detected heteronuclear multiple-bond correlation  
COSY Correlation Spectroscopy  
NOESY Nuclear Overhauser Effect Spectroscopy   
δ Chemical shift  
J Coupling Constant 
d Doublet 
dd Doublet of doublet 




































A (15)和苯甲内酰胺类的化合物penicillactam (19)，另一个化合物 (20) 在本论文
当中首次对其波谱数据进行报道。其余已知化合物分别为：黑麦酮酸F (1)，
2-pyruvoylaminobenzamide (2)，麦角甾醇 (3)，角甾-6, 22-二烯-3β, 5α, 8α-三
醇 (4)，4-(2-羟基乙醇)苯酚 (5)，4-羟基苯甲酸 (6)，3-羟基苯甲酸 (7)，环-(脯
氨酸-酪氨酸) (8)，环-(丙氨酸-异亮氨酸) (10)，环-(丙氨酸-亮氨酸) (11)，对羟基
苯甲酸甲酯和3，4-二羟基苯甲酸甲酯 (12)， macrophorin A (13)，3,4-二羟基苯























As the industry pollution and environment destruction become worse day by day, 
malignant tumor attacks rate has been increasing rapidly every year and the routine 
anti-tumor drugs usually possess severe side effects. Nowadadys searching for novel 
anti-tumor drugs with slight side effect is one of the most significant tasks in 
pharmaceutical chemistry research field. The discovery of natural active ingredient 
from deep sea is foundation and source in marined drugs exploitation. Marine natural 
products put up a great extensive bioactivities, such as anti-tumor, antibiosis, antivirus, 
immune suppression and so on. Because of the particular extreme conditions that 
include high pressure, low temperature, oxygen deficit, exteme PH value, high salinity, 
high metallicity, empty illumination, poor nutrition, high halogen the deep sea 
microorganisms live in, they can produce secondary metabolites with novel structures, 
distinctive functions and slight side effects. The secondary metabolite is one of the 
most important sources in hunting for novel anti-tumor drugs. Marine fungi’s 
adaptability to the particular deep sea surroundings contributes greatly to the unique 
metabolic pathway and heredity backgrounds. Thus marine fungus usually can 
generate bioactive metabolites and the research for these bioactive metabolites is of 
great significance in seeking for new drugs. 
In my essay, Penicillium sp.F11 strain from Lau Basin 1744 meters deep 
sediments was chosen for futher research because of its super cytotoxicity. After 
large scale culture, fermentation, extraction, concentration of Penicillium sp.F11, its 
secondary metabolites were obtained. We used high efficient separation methods and 
preparative techniques for the following isolations. By utilizing NMR, MS 
techniques twenty compounds structure was identified and their cytotoxicity against 
HT1080, Cne2 and Bel7402 cell lines was also evaluated. There are two novel 
structure penicillone A (Compound 15) and penicillactam (Compound 19). Though 















paper. Other known compounds were identified by comparison of their spectroscopic 
data with literature values. They were characterized as: secalonic acid F (1), 
2-pyruvoylaminobenzamide (2)，ergosterol (3), 5α,8α-ergosta-6,22-diene-3β,5,8-triol 
(4), 4-(2-hydroxyethyl)phenol (5), 4-hydroxybenzoicacid (6), 3-hydroxybenzoicacid 
(7), cyclo(Pro-Tyr) (8), cyclo(Ala-Ile) (10), cyclo(Ala-Leu) (11), methyl 
p-hydroxybenzoate and 3,4-dihydroxybenzoate (12, mix), macrophorin A (13), 
3,4-dihydroxybenzoicacid (14), hydro-chloromycetin (16), acetylchloromycetin (17), 
cyclo(Phe-Phe) (18)，2-(2-hydroxypropionylamino) benzamide (21). Penicillone A 
not only exhibits moderate cytotoxic activities but also demonstrates selective 
activity against different tumor cell lines. 
In a word, our study indicated that deep-sea marine microorganism metabolites 
were reliable resources for compound precursors with structural novelty, antitumor 
or other bioactivity. Researching on the secondary metabolites from deep sea 
microorganism is greatly meaningful in exploiting marine new resources, seeking for 
novel anti-tumor precursor with high efficient and low toxicity.  
 






















摘 要 ········································································································ II 
ABSTRACT·························································································· III 
第一章 绪 论 ·························································································· 1 
1. 海洋抗肿瘤天然产物研究概况 ·····································································2 
2.  从海洋微生物寻找抗肿瘤药物的巨大优势 ·················································4 
3.  海洋细菌的抗肿瘤代谢产物研究 ·································································5 
4.  海洋放线菌的抗肿瘤代谢产物研究 ·····························································6 
5.  海洋真菌的抗肿瘤代谢产物研究 ·································································8 
6.  课题的研究目的、内容和意义 ···································································15 
参 考 文 献 ········································································································17 
第二章 PENICILLIUM SP F11 活性代谢产物的分离、鉴定及结构
解析 ··························································································· 22 
1. 技术路线 ········································································································22 
2. 实验部分 ········································································································23 
2.1 仪器、试剂与材料···················································································23 
2.2 发酵与分离 ······························································································25 
3. 结果与分析 ····································································································26 
3.1 新化合物的结构解析···············································································27 
3.2 已知化合物的结构鉴定···········································································31 
4. 小结与讨论 ····································································································51 
参 考 文 献 ········································································································55 















1. 实验部分 ···········································································································57 
1.1 材料················································································································57 
1.2 方法················································································································58 
2. 结果 ·····················································································································59 
3. 讨论 ·····················································································································60 
参 考 文 献 ·············································································································61 
第四章 结论与展望 ················································································· 62 
1. 结论 ···················································································································62 
2. 展望 ···················································································································63 
附 录 ·········································································································· 65 
研究生期间发表的文章 ········································································· 109 



















ABSTRACT IN CHINESE··································································· II 
ABSTRACT IN ENGLISH································································· III 
CHAPTER 1 INTRODUCTION ·························································· 1 
1. SUMMARY OF ANTI-TUMOR MARINE NATURAL PRODUCT RESEARCH ·············2 
2. HUGE ADVANTAGES IN MARINE MICROORGANISMS RESEARCH ······················4 
3.  SECONDARY ANTINEOPLASTIC METABOLITES FROM MARINE-BACTERIA·······5 
4.  SECONDARY ANTINEOPLASTIC METABOLITES FROM 
MARINE-ACTINOMYCETE ··············································································6 
5.  SECONDARY ANTINEOPLASTIC METABOLITES FROM MARINE-FUNGUS ··········8 
6.  AIMS, CONTENT AND SIGNIFICANCE OF RESEARCH PROJECT ·······················15 
REFERENCES ·······································································································17 
CHAPTER 2 STUDIES ON THE METABOLITES OF A 
MARINED FUNGUS PENICILLIUM SP. F11········ 22 
1. RESEARCH TECHNICAL ROUTE········································································22 
2. EXPERIMENT SECTION ····················································································23 
2.1 Apparatus, reagents and material·································································23 
2.2 Fermentation and isolation ··········································································25 
3. RESULT AND ANALYSIS·····················································································26 
3.1 Structural Identification of the new compounds ·········································27 
3.2 Identification of the known compounds ······················································31 
4. BRIEF SUMMARY AND DISCUSSION ··································································51 
REFERENCES ·······································································································55 
CHAPTER 3 BIOLOGICAL ACTIVITY RESEARCH·················· 57 















1.1 Materials ······································································································57 
2.2 Methods ·······································································································58 
3. RESULT ANALYSIS ····························································································59 
4. DISCUSSION ·····································································································60 
REFERENCES ·······································································································61 
CHAPTER 4 CONCLUSIONS AND PROSPECTS ························ 62 
1. CONCLUSION ···································································································62 
2. PROSPECTS······································································································63 
APPENDIX···························································································· 65 


















第一章 绪 论 
恶性肿瘤极大的危害着人类的健康。在 1991 年到 2000 年间，全球癌症发
病及死亡人数均增长 22%。2002 年世界新发肿瘤人数 1100 万，当年死亡病例









源药物。1981－2006 年 6 月，人们所得到的 974 种新小分子新化学实体（NCEs，
New Chemical Entities）中有 58％与天然产物有关，纯粹天然产物数量占 6%。 自
1940 年以来所有 175 个有效抗肿瘤先导化合物中，和天然产物相关的化合物占
54%，纯粹天然产物占 14%（图 1-1）[2]。 
 
1981~2006 年 6 月间的小分子新化学实体 1940 年-2006 年 6 月间的抗肿瘤先导化合物 
图 1-1 小分子新化学实体及抗肿瘤活性先导化合物来源分布图 
Figure 1-1 Distribution of NCEs and anticancer drugs untill 2006 
N: 天然产物；ND: 来源于天然产物，通常经过半合成的化学修饰；S: 完全化学合成；S∗: 完全化学合成， 
但是药效团来自天然产物；NM：根据从天然产物获得的信息/知识进行药物设计；S/NM：完全化学合成，































表 1-1 处于临床研究阶段的海洋来源肿瘤治疗药物 

















量结构新颖的具有抗菌、抗肿瘤、抗炎症等生物活性的天然产物（图 1-2）[11, 12]。 
 
图 1-2  海洋天然药物按门分类的分布图 








































 (2) 从数量上看，海洋蕴藏丰富的生物资源，占地球生物资源的 80%。美








halichondrin B 或 ishomohalichondrin B 为主要活性物质的抗癌药物要商业化，
根据临床前试验数据计算，每年大约需要 5kg 化合物，如果从海绵中分离至少






















胞菌属 (Pseudomonas)、土壤杆菌属 (Agrobacterium )、弧菌属 (Vibrio)、微球
菌属 (Micrococcus)、芽孢杆菌属 (Bacillus)、肠杆菌属 (Enterubacrerium)、交




















Matsuda等[24]从海洋假单胞菌Pseudomonas sp .WA K-1中分离纯化得到1个硫
酸多聚糖B-1 (3)。结果发现其对39株肿瘤细胞系有显著的抗肿瘤活性，平均IC50 
为63.2 mg·L−1, 其中对B-1 高度敏感的菌株集中在中枢神经系统肿瘤细胞和肺癌
细胞。细胞形态学观察和DNA ladder电泳分析表明B-1通过诱导细胞凋亡发挥抗
肿瘤作用。 
Zheng等 [25]从海绵Hymeniacidon perleve 中分离出29种海洋细菌, 其中NJ 
6-3-1发酵物经色谱分析、结构鉴定 , 得到1个β-咔啉生物碱Norharman (4)。 
Norharman (4) 在体外对人宫颈癌细胞HeLa和胃癌细胞BGC-823具有显著的细胞
毒活性，IC50 为5 mμg·mL-1。 
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